Table 1.
Measured outcomes of Rezum at 12 months.
| Authors | Year |
N =
total n = Rezum |
IPSS (%) reduction | Qmax (%) improvement | PVR (%) reduction | IPSS QoL (%) reduction | IIEF-EF (%) improvement | Complications (related adverse events), n |
Supported by industry | |
|---|---|---|---|---|---|---|---|---|---|---|
| Clavien–Dindo I-II | Clavien–Dindo III–V | |||||||||
| McVary and Roehrborn (RCT)10 | 2017 |
N = 201 n = 136 |
53 | 55 | 5 | 52 | −1 | Dysuria: 16.9% Haematuria: 11.8% Frequency and Urgency: 5.9% |
N = 3 (2.2%) (urinary retention =1, hospitalization due to nausea and vomiting =1, NOS = 1) |
Yes |
| Dixon and colleagues (pilot)8 | 2016 |
N = 65 n = 65 |
58 | 55 | 32 | 61 | 11 | Urinary retention: 33.8% Dysuria: 21.5% Urgency: 20% UTI (suspected): 20% Haematuria: 13.8% Poor stream: 13.8% Pain/discomfort: 10.8% Nocturia: 7.7% Frequency: 6.2% Fever: 4.6% Dribbling: 3.1% Scrotal pain: 3.1% Incontinence: 1.5% |
N = 3 (4.6%) (urinary retention = 1, poor stream = 1, urinary frequency = 1) |
Yes |
| Roehrborn and colleagues (crossover)12 | 2017 |
N = 53 n = 53 |
56 | 53 | 17 | 55 | 18 | Dysuria: 18.9% Haematuria: 11.3% |
N = 3 (5.6%) (bladder neck contracture = 1, bladder stone formation =1, sepsis = 1) |
Yes |
| Darson and colleagues11 | 2017 |
N = 131 n = 131 |
45 | 51 | 35 | 38 | n/a | Acute urinary retention: 10.7% | Nil | No |
IIEF-EF, international index of erectile function; IPSS, international prostate symptom score; n/a, not applicable; NOS, not otherwise specified; PVR, post-void residual; Qmax, urine flow rate; QoL, quality of life; RCT, randomized controlled trail; UTI, urinary tract infection.